Impact of Nicotinamide Riboside (NR) on Kidney Function in Patients Undergoing Cardiac Surgery

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorInstituto Nacional de Cardiologia Ignacio Chavez

About this trial

Acute kidney injury (AKI) associated with cardiac surgery is the most important complication in adult patients undergoing open heart surgery and is associated with increased mortality and morbidity. In patients in intensive care units, it is the second most common type of AKI after AKI secondary to sepsis. There is currently no specific treatment for AKI. Supportive measures include renal support therapy for patients with severe AKI, and mortality in this subgroup of patients exceeds 50%. Increasing NAD+ with niacinamide has been shown to prevent various etiologies of experimental AKI in mice, and an early pilot study has shown both increased NAD levels following administration of nicotinamide riboside with pterostilbene NPRT and the safety of niacinamide in patients undergoing cardiac surgery.

Eligibility criteria

Qualifiers

Heart valve replacement surgery

Sign of informed consent

Disqualifiers

Allergy to any of the components

Platelet count less than 100,000

Weight less than 50Kg or over 100Kg

Any type of infectious disease (e. g, Endocarditis)

Trial design

Treatments tested in this trial

  • Nicotinamide riboside
  • Placebo

Treatment groups

100 Participants
are divided into 2 treatment groups